-
1.发明授权Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems 有权碳酸酐酶抑制剂持续释放眼内药物递送系统公开(公告)号：US08591885B2
公开(公告)日：2013-11-26
申请号：US11931769
申请日：2007-10-31
CPC分类号： A61K9/0051 , A61F9/0008 , A61K48/0041
摘要： Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
摘要翻译： 生物相容性眼内药物递送系统包括碳酸酐酶抑制剂治疗剂和植入物，微粒，多种植入物或微粒形式的聚合物组分及其组合。 治疗剂以生物活性形式释放，例如，当释放到患者的眼睛中时，治疗剂可以保持其三维结构，或者治疗剂可以具有改变的三种。 植入物可以放置在眼睛中以治疗或减少一种或多种眼部病症的发生，例如视网膜损伤，包括青光眼和增生性玻璃体视网膜病变等。
-
公开(公告)号：US20110263611A1
公开(公告)日：2011-10-27
申请号：US13178277
申请日：2011-07-07
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
IPC分类号： A61K31/496 , A61P27/06 , A61K31/5377 , A61P27/02
CPC分类号： C07D213/82 , A61K9/0051 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K47/34 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D417/06 , Y02A50/401
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
摘要翻译： 本发明涉及药物递送系统，其包括眼部植入物，其包括能够调节酪氨酸激酶信号转导以调节，调节和/或抑制异常细胞增殖的有机分子，所述聚合物用于控制聚合物， 改变，调节和/或缓慢释放治疗组分到其中放置所述复合物的眼睛的环境中。
-
3.发明申请Methods and compositions for treatment of ocular neovascularization and neural injury 审中-公开用于治疗眼部新血管形成和神经损伤的方法和组合物公开(公告)号：US20100129435A1
公开(公告)日：2010-05-27
申请号：US12381547
申请日：2009-03-12
CPC分类号： A61K31/13 , A61K31/498 , A61K38/185 , A61K38/57 , A61K41/0057 , A61K41/0071
摘要： Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor.
摘要翻译： 用于治疗眼新生血管形成和黄斑变性的方法和组合物。 本发明包括将光动力疗法与神经保护剂和新生血管形成抑制剂的给药结合在一起。
-
公开(公告)号：US11078262B2
公开(公告)日：2021-08-03
申请号：US11742350
申请日：2007-04-30
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
-
公开(公告)号：US20120238558A9
公开(公告)日：2012-09-20
申请号：US12380493
申请日：2009-02-26
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
IPC分类号： A61K31/404 , A61P27/00 , A61K31/496 , A61K31/541 , A61K31/454 , A61K31/5377
CPC分类号： C07D405/04 , A61K9/0051 , A61K9/5031 , A61K31/397 , A61K31/404 , A61K31/41 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/82 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
公开(公告)号：US20090196906A1
公开(公告)日：2009-08-06
申请号：US12319356
申请日：2009-01-05
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster
IPC分类号： A61F2/14 , A61K31/44 , A61K31/444 , A61K31/4439 , A61K31/4436 , A61K31/5377 , A61K31/496 , A61K31/541 , A61K31/4545
CPC分类号： C07D213/82 , A61K9/0051 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K47/34 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D417/06 , Y02A50/401
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
7.发明申请公开(公告)号：US20080268051A1
公开(公告)日：2008-10-30
申请号：US11742350
申请日：2007-04-30
IPC分类号： A61K9/00 , A61P27/02 , A61K38/00 , A61K31/711 , A61K39/395
CPC分类号： C07K16/22 , A61K9/0048 , A61K9/08 , A61K38/39 , A61K47/34 , A61K2039/505 , C07K2317/24 , C12N15/1138 , C12N2310/14 , C12N2310/315 , C12N2310/317 , C12N2310/332 , C12N2320/32
摘要： Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25° C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25° C. is in the range of from about 80,000 cps to about 300,000 cps.
摘要翻译： 提供了抗血管生成组合物，以及使用这些组合物的方法，其可用于注射到人眼玻璃体中。 这样的组合物包括以治疗有效量存在的MAAC溶液或颗粒，粘度诱导组分和水性载体组分。 组合物在约25℃下的粘度为0.1 /秒的剪切速率为至少约10cps或约100cps。 在优选的实施方案中，25℃下的粘度在约80,000cps至约300,000cps的范围内。
-
公开(公告)号：US08143410B2
公开(公告)日：2012-03-27
申请号：US12319356
申请日：2009-01-05
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster
IPC分类号： C07D211/72 , C07D241/00 , A61K31/50 , A61K31/44
CPC分类号： C07D213/82 , A61K9/0051 , A61K31/44 , A61K31/4436 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K47/34 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D417/06 , Y02A50/401
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
摘要翻译： 本发明涉及药物递送系统，其包括眼部植入物，其包括能够调节酪氨酸激酶信号转导以调节，调节和/或抑制异常细胞增殖的有机分子，所述聚合物用于控制聚合物， 改变，调节和/或缓慢释放治疗组分到其中放置所述复合物的眼睛的环境中。
-
公开(公告)号：US20090286773A1
公开(公告)日：2009-11-19
申请号：US12380493
申请日：2009-02-26
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. DeVries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
IPC分类号： A61K31/404 , A61K31/454 , A61K31/5377 , A61K31/496 , A61K31/541 , A61P27/00
CPC分类号： C07D405/04 , A61K9/0051 , A61K9/5031 , A61K31/397 , A61K31/404 , A61K31/41 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/82 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
摘要翻译： 本发明涉及药物递送系统，其包括眼部植入物，其包括能够调节酪氨酸激酶信号转导以调节，调节和/或抑制异常细胞增殖的有机分子，所述聚合物用于控制聚合物， 改变，调节和/或缓慢释放治疗组分到其中放置所述复合物的眼睛的环境中。
-
公开(公告)号：US08455656B2
公开(公告)日：2013-06-04
申请号：US12380493
申请日：2009-02-26
申请人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
发明人： Lon T. Spada , Jane Guo Shiah , Patrick Hughes , Thomas C. Malone , Gerald W. Devries , Jeffrey L. Edelman , Julie A. Wurster , Xialing Guo , Sougato Boral
IPC分类号： A61K31/40 , A61F9/007 , C07D213/00
CPC分类号： C07D405/04 , A61K9/0051 , A61K9/5031 , A61K31/397 , A61K31/404 , A61K31/41 , A61K31/454 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K45/06 , C07D213/82 , C07D401/06 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/06 , C07D413/06 , C07D413/14 , C07D417/06
摘要： The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.03 秒)
